Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.

Fritz Offner,Tadeusz Robak,Ann Janssens,Govind Babu Kanakasetty,Janusz Kloczko,Sebastian Grosicki,Jiri Mayer,Panagiotis Panagiotidis,Anna Schuh,Andrew R. Pettitt,Marco Montillo,Olena Werner,Ghislaine Vincent,Sadhvi Khanna,Peter Hillmen

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.

2019

Fritz Offner
Tadeusz Robak
Ann Janssens
Govind Babu Kanakasetty
Janusz Kloczko
Sebastian Grosicki
Jiri Mayer
Panagiotis Panagiotidis
Anna Schuh
Andrew R. Pettitt
Marco Montillo
Olena Werner
Ghislaine Vincent
Sadhvi Khanna
Peter Hillmen

7528Background: Previously in the COMPLEMENT 1 study, treatment with OFA and CHL in pts with untreated CLL had shown a significant improvement in the progression-free survival (PFS) compared with C...

Keywords:

Ofatumumab
Pathology
Chronic lymphocytic leukemia
Chlorambucil
Oncology
Internal medicine
Medicine
long term follow up

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations